Chardan lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $54 from $62 and keeps a Buy rating on the shares after the company reported Q4 and FY24 results and highlighted upcoming catalysts across its pipeline. The firm updated its model for Q4 financials, including dilution from the December offering, and pushed out initial ex vivo lenti revenues to 2026 given the lag between approval and initial commercial treatment observed for other ex vivo HSC therapies, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Positive Outlook for Rocket Pharmaceuticals Amidst Regulatory Progress and Financial Stability
- Promising Pipeline and Market Opportunities Drive Buy Rating for Rocket Pharmaceuticals
- Rocket Pharmaceuticals reports Q4 EPS (62c), consensus (72c)
- Rocket Pharmaceuticals price target lowered to $48 from $49 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today